Case of benralizumab-induced exacerbations of chronic spontaneous urticaria

Eli Magen; Irina Komarova; Israel Magen; Sofia Phirtskhalava

doi:10.1002/ccr3.5930

Case of benralizumab-induced exacerbations of chronic spontaneous urticaria

Clin Case Rep. 2022 Jun 19;10(6):e05930. doi: 10.1002/ccr3.5930. eCollection 2022 Jun.

Authors

Eli Magen^{1

2}, Irina Komarova¹, Israel Magen³, Sofia Phirtskhalava³

Affiliations

¹ Department of Medicine C, Clinical Immunology and Allergy Division Barzilai University Medical Center Ben-Gurion University of the Negev Ashkelon Israel.
² Leumit Health Services Tel Aviv-Yafo Israel.
³ Tbilisi State Medical University Tbilisi Georgia.

Abstract

The role of IL-5 in chronic spontaneous urticarial (CSU) is unclear. It may be that benralizumab is an important bidirectional modifier of CSU; that is, blocking IL-5 may improve CSU in some patients, but it is possible that it may worsen CSU in others.

Keywords: benralizumab; chronic; exacerbation; induced; spontaneous; urticaria.

Publication types

Case Reports